Age-Related Macular Degeneration (Vegf): Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis

  • ID: 3797419
  • Drug Pipelines
  • 190 pages
  • Datamonitor Healthcare
1 of 3
Eylea overtakes Lucentis in 2015 to become the highest selling anti-VEGF treatment for wet AMD, just four years after its first launch.

This report addresses the following questions:

- How do treatment practices vary in the US and EU between the three major VEGF inhibitors?
- Why has Eylea been able to quickly position itself as a standard-of-care and overtake Lucentis?
- What factors will contribute to the expansion of the wet AMD market value over the next ten years?
- What impact will future biosimilar VEGF therapies have on the branded market?
- How should pipeline therapies position themselves for maximum commercial success?
Note: Product cover images may vary from those shown
2 of 3
FORECAST: WET AGE-RELATED MACULAR DEGENERATION

- Executive Summary
- Market Overview and Trends
- Market Definition and Methodology
- abicipar pegol
- Avastin (bevacizumab)
- brolucizumab
- Eylea (aflibercept)
- Fovista (pegpleranib)
- Lucentis (ranibizumab)
- squalamine
- Primary Research Methodology

TREATMENT: WET AGE-RELATED MACULAR DEGENERATION

- Executive Summary
- Primary Research Methodology
- Disease Definition and Diagnosis
- Patient Segmentation
- Current Treatment Options
- Treatment Trends

EPIDEMIOLOGY: AGE-RELATED MACULAR DEGENERATION

- Executive Summary
- Disease Background
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations

MARKETED DRUGS: WET AGE-RELATED MACULAR DEGENERATION

- Executive Summary
- Product Overview
- Product profile: Avastin
- Product profile: Eylea
- Product profile: Lucentis
- Product profile: Macugen
- Product profile: Visudyne

PIPELINE: WET AGE-RELATED MACULAR DEGENERATION

- Executive Summary
- Clinical Pipeline Overview
- Clinical Trial Design in Wet AMD
- The Future of Treatment in Wet AMD
- Product profile (late stage): Fovista
- Product profile (late stage): abicipar pegol
- Product profile (late stage): brolucizumab
- Product profile (late stage): squalamine
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll